arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Orchestra BioMed Holdings, Inc.

OBIO
$5.61 ▼ -0.36 (-6.03%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
25 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Orchestra BioMed Holdings, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $358.0M
Dividend Yield —
Revenue Growth -89.5% ↘
Op. Margin None
ROIC None
FCF / Share $-0.31 ↗
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

25-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$88.00K
↓ -89.5% —
Net Income Profit after all expenses
$-20.69M
↓ -10.3% —
FCF / Share Free cash flow per share
$-0.31
↑ +13.9% —
Long-Term Debt Long-term obligations
$15.00M
— 0.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Cash Quality ↑
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 6 years · 25 quarters